OBJECTIVES: Extended donors (EDs) are safely used to increase the donor pool in lung transplantation (LT), but their influence in critically ill patients (extended recipients [ERs]) remains controversial. We compared LT outcomes matching optimal donors (ODs) or EDs with optimal recipients (ORs) or ERs.
INTRODUCTION
Fifty years have passed since Hardy et al. [1] performed the first human lung transplantation (LT). Aiming for optimal results, the early transplant surgeons chose ideal donors: young, non-smokers, from the own transplant group, with very short ischaemic times and with PaO 2 /FiO 2 ratios >300 mmHg. As the LT procedure matured, transplant groups took more risks and relaxed the previously strict donor criteria, starting to use more marginal donors, after several reports suggesting equivalent outcomes. Meanwhile, as the procedure gained widespread success, the indications expanded significantly, and the number of candidates waiting markedly overweighed the number of available donor lungs. At present, although LT remains an established therapy for patients with parenchymal and pulmonary vascular lung disease, limited organ supply currently limits this option, and has led to an increased disparity between the number of suitable lung donors and the number of potential recipients, with many patients dying on the waiting lists.
Nowadays, brain-dead donors remain the main source of lung grafts for transplantation, but only 20% of these donors provide lungs suitable for transplantation [2] . A number of strategies have been advocated to expand the lung donor pool. Regarding public education and donor awareness campaigns, Spain is the country with the highest organ donation rate (34.8 per million populationppm) [3] . However, LT rates in Spain (5 ppm) compare unfavourably with other European countries like Austria (14.3 ppm) and Belgium (10.1 ppm) http://www.eurotransplant.org/cms/mediaobject.php? file=ar_2011.pdf (accessed April 2013). Aggressive medical management of the multiorgan donor has resulted in an increase in the rate of organs offered from 21 to 57%, and in the overall organ procurement rate from 11.5 to 25.5% [4] . Other strategies such as livinglobar LT, organ donation after cardiac death (non-heart-beating donors) and ex vivo lung perfusion can also increase the number of organs available, but are technically and logistically demanding, and thus, just a few groups perform them worldwide. Given the desperate need to expand the lung donor pool, transplant centres have relaxed the strict donor-selection criteria with acceptable shortterm outcomes [5] . But the possible influence of pre-transplant recipient characteristics on LT outcomes after receiving either an optimal or a marginal donor lung has not been thoroughly addressed. So what is the major concern when transplanting marginal lung grafts: the fear of liberalizing lung donor criteria or of using non-ideal grafts in very ill recipients? To answer this question, we compared LT outcomes matching optimal or extended donors (ODs or EDs) with optimal or extended recipients (ORs or ERs).
PATIENTS AND METHODS

Study population
Three hundred and sixty-five consecutive LTs performed between October 1993 and December 2012 at the Reina Sofia University Hospital were retrospectively reviewed. Eleven retransplantations and 1 heart-LT were not included in the analysis. On occasion, pulmonary twinning procedures were done, so both the lungs of a single donor were transplanted into two separate recipients. EDs were defined as those meeting, at least, two of the following criteria: (i) age >55 years, (ii) PaO 2 /FiO 2 < 350 mmHg on 100% oxygen with 5 cmH 2 O positive end-expiratory pressure, (iii) pulmonary infiltrates on chest radiograph, (iv) presence of purulent secretions on bronchoscopy, (v) ischaemic times >6 h (if single LT [SLT]) or >9 h (if double LT [DLT] ) and (vi) tobacco history >20 pack-years. Donor arterial PO 2 was based on the final measurement before harvesting, rather than the initial measurement at the time of lung offer. Donors with oxygenation ratios <300 mmHg regardless of aggressive resuscitation and management were not considered for transplantation in any case. ODs met all of the traditionally accepted lung transplant donor-selection criteria [6] . We considered a receptor to be 'extended' when having at least one of the following: (i) pulmonary fibrosis or pulmonary hypertension, (ii) age older than 60 years, (iii) on mechanical ventilation before LT and (iv) on cardiopulmonary bypass longer than 2 h. ORs fulfilled all of the standard criteria defined by the International Society for Heart and Lung Transplantation (ISHLT) [7] .
Study design
For the purposes of this study, donors and recipients were classified as optimal or extended, so a total of four groups were created: OD, ED, OR and ER. A subgroup analysis was performed among the four possible combinations: Group 1: OD to OR; Group 2: OD to ER; Group 3: ED to OR and Group 4: ED to ER. Our primary end-points were 30-day mortality, development of primary graft dysfunction (PGD), freedom from bronchiolitis obliterans syndrome (BOS) and survival. Secondary end-points were postoperative complications, need for cardiopulmonary bypass, ICU stay and acute rejection (AR) episodes. Thirty-day mortality, PGD, freedom from BOS, long-term survival and other transplant outcomes were compared between OD and ED, OR and ER and among the four groups of study.
Donor lung assessment and procurement
Donor and recipient matching with regard to thoracic dimensions and ABO compatibility was performed in every case. Lung donor procurement followed the standard technique of combined cardiopulmonary extraction [8] . The lungs were flushed antegradely via the main PA, venting the perfusate through the left atrial appendage. Once on the back table, an additional retrograde perfusion of the donor lung through the pulmonary veins was performed to optimize lung preservation [9] . Modified Eurocollins ® (60 ml/kg; 4°C, 30 cmH 2 O) was the preservation solution used until year 2001, when Perfadex ® solution (Vitrolife, Gothenburg, Sweden) was introduced routinely. The use of different lung preservation solutions was equally distributed among the four groups of study.
Lung transplantation procedure
Recipients were chosen by the transplant team on the basis of blood type, size match, recipient status and time on the waiting list. Intraoperative cardiopulmonary support with standard bypass during LT is used selectively at our Institution: (i) during the pneumonectomy or the implantation of the first lung graft, when the native lung is not able to maintain adequate gas exchange, or in case of haemodynamic instability. (ii) During the implantation of the second graft, due to the development of graft dysfunction. A fibreoptic bronchoscopy was performed at the end of the procedure to check the status of the bronchial anastomosis and to aspirate secretions.
Postoperative management
Lung transplant recipients received a triple-drug maintenance immunosuppressive regimen consisting of a calcineurin inhibitor (cyclosporine or tacrolimus), plus cell-cycle inhibitors (azathioprine or mycophenolate mofetil) and steroids. Cytolytic therapy was not used systematically. AR episodes were diagnosed by clinical criteria and, on occasion, with the demonstration of perivascular mononuclear cellular infiltrates by transbronchial lung biopsy. The use of different immunosuppression regimens was equally distributed among the four groups of study.
Definitions
PGD was defined following the Statement of the ISHLT [10] . To rule out possible cases with low oxygenation ratios within the first 24 h post-transplant that could improve early thereafter (reperfusion injury, post-transplant pulmonary oedema), we only selected those cases with persistent low PO 2 and pulmonary infiltrates in chest radiographs at 72 h post-transplant (PGD grades 2-3 at 72 h). BOS was graded and defined following the criteria of the ISHLT [11] . For the purposes of this study, BOS grades 2 or 3 were considered for the analysis. Airway complication was defined as a finding of dehiscence, stenosis or malacia of the anastomosis requiring either intervention (surgery, dilatation, debridement, laser therapy or stent placement) or only conservative measures.
Data collection
The medical records of all patients who underwent LT at our Institution from 1993 to 2012 and data from the computerized database were retrospectively reviewed. The donor-related variables included in the analysis were gender, age, ABO blood group, PaO 2 /FiO 2 at the time of organ retrieval, duration of mechanical ventilation, ICU stay, the cause of death, smoking history, results of chest X-rays and bronchoscopic findings. The preoperative recipient variables recorded were age, gender, ABO blood group, transplant indication and mechanical ventilation before LT. The intraoperative variables collected were the type of transplantation (SLT/DLT), the need for cardiopulmonary bypass and the ischaemic time of the first and second lung grafts. Postoperative variables analysed were PaO 2 /FiO 2 ratio within the first 24 postoperative hours, duration of mechanical ventilation, AR episodes (overall, within 1 month post-transplant, between 2 and 3 months post-transplant and after 3 months post-transplant), freedom from BOS, 30-day mortality and survival. Survival and freedom from BOS were analysed and compared with those obtained from the Kaplan-Meier method and log-rank test.
Statistical analysis
Continuous variables are expressed as means ± standard deviation. Categorical variables are expressed as counts and proportions with 95% confidence intervals (95% CIs). Differences with P-values <0.05 were considered significant. The statistical analysis was performed using SPSS (SPSS 20.0 for Mac: SPSS, Inc., Chicago, IL, USA).
RESULTS
For the 365 LTs performed, we had 136 (37.2%) EDs compared with 229 (62.8%) ODs. With regard to transplant procedures, there were 214 DLT (58.5%) and 151 SLT (41.5%). Among the EDs, 44 had a smoking history of >20 pack-years (in 17% of donors, data regarding smoking history were not available), 25 were older than 55 years, 24 had a PaO 2 /FiO 2 ratio between 300 and 350 mmHg, 66 presented an abnormal chest X-ray, 168 donors presented abnormal bronchoscopic findings, 61 had an ischaemic time for the first graft > 6 h and 18 had an ischaemic time for the second graft >9 h. The main extended criterion among recipients was pulmonary fibrosis or pulmonary hypertension diagnosis (107 cases), followed by age older than 60 years (60 cases), mechanical ventilation pretransplantation (40 cases) and intraoperative cardiopulmonary bypass longer than 2 h (13 cases).
Extended donors vs optimal donors
The comparative analysis of transplant outcomes with regard to donor status (EDs vs ODs) is given in Table 1 . Gender distribution was similar between both groups of donors. As they were defining criteria, EDs were older, with lower PaO 2 /FiO 2 ratios, with longer graft ischaemic times, and were ventilated for longer periods (Table 1) . Lung grafts from EDs were transplanted more frequently Quantitative variables are expressed as means ± standard deviation. Qualitative variables are expressed as frequencies and proportions in parentheses (% within each study group). PGD2-3 at T72: primary graft dysfunction grades 2 or 3 at 72 h post-transplant.
into older recipients (recipient mean age of 45 ± 16 years compared with 40 ± 17 years when optimal grafts were used, P = 0.02).
In addition, the proportion of DLTs performed was lower when the grafts came from EDs, and oxygenation ratios in the recipients of extended grafts were slightly worse than those in optimal grafts. On the contrary, donor cause of death, transplant indication, need for cardiopulmonary bypass, development of PGD and 30-day mortality were not different between both groups of donors (Table 1) .
Extended recipients vs optimal recipients
The comparative analysis of transplant outcomes with regard to recipient status (ORs vs ERs) is depicted in Table 2 . Gender distribution showed a male-to-female predominance among ERs. Also, ERs were significantly older and received lung grafts from older donors. Mean donor PaO 2 /FiO 2 was worse in ERs than in ORs ( Table 2 ). As expected, transplant indication was significantly different in ERs compared with ORs. As pulmonary fibrosis was a defining criterion of ERs in our series, in the groups with ERs, the main LT indication was idiopathic pulmonary fibrosis (IPF) followed by chronic obstructive pulmonary disease (COPD), cystic fibrosis and others. On the contrary, in the optimal group the main indication was COPD followed by cystic fibrosis and others. Also, the transplant procedure varied between ERs and ORs. Thus, among the ERs, more SLTs were performed compared with ORs (Table 2) . Recipient PaO 2 /FiO 2 at 24 h post-transplant was worse in the extended group than in the optimal group, and also there was a trend towards an increased 30-day mortality among ERs, although not significant (43 deaths, 23.5% vs 29 deaths, 15.9%).
The duration of mechanical ventilation in the donor, donor cause of death, ischaemic time of the first graft and development of PGD was not different between ERs and ORs ( Table 2) .
Analysis of four donor/recipient groups
Comparative data among all donor/recipient (D/R) pairs are given in Table 3 . Overall, gender distribution was similar among the four D/R pairs. Donors were older in the OD/ER, ED/OR and ED/ER groups compared with OD/OR group. The length of donor intubation was also significantly longer in the ED/OR and ED/ER groups compared with OD/OR and OD/ER groups. As expected, transplant indication was significantly different in ERs compared with ORs. Thus, the main indications in both OR groups were cystic fibrosis and COPD, whereas in ER groups, the main indication was pulmonary fibrosis. With regard to the transplant procedure, SLT was the technique of choice for ERs (Table 3) . LT to an ER had a negative impact on the postoperative length of mechanical ventilation and on the mean intensive care unit length of stay. There was a trend towards an increase in the number of AR episodes between the second and third months post-transplant among ED/OR patients (mean: 0.37) and ED/ER patients (mean: 0.22), compared with OD/OR and OD/ER patients (mean: 0.16 and 0.17, respectively), P < 0.001. However, no difference was found in the number of AR episodes in the first month post-transplant, after the third month post-transplant or in the total number of AR episodes (data not shown).
There was no difference in donor cause of death, donor PaO 2 / FiO 2 , recipient age, need for bypass, recipient PaO 2 /FiO 2 in the first 24 h, development of PGD and 30-day mortality for the combination of donors and recipients (Table 3) .
Bronchiolitis obliterans syndrome
The analysis of BOS included only those recipients surviving the first postoperative year. There was a non-significant trend towards (Fig. 1B) .
When the four groups of study were compared, subtle differences in the onset of BOS persisted within the OD groups: OD/OR group 8.0 years [95% CI: 5.9-10.1], OD/ER group 9.2 years [95% CI: 6.9-11.3], ED/OR group 6.7 years [95% CI: 4.1-9.4] and ED/ER group 6.4 years [95% CI: 3.2-9.6], P = 0.54 (Fig. 1C) .
Survival
Actuarial survival of lung transplant recipients according to donor and recipient status is shown in Fig. 2 . Interestingly, no significant differences in survival were observed between patients receiving grafts from ODs (median survival: 4.1 years [95% CI: 2.5-5.6]) and those receiving grafts from EDs (median survival: 6.6 years [95% CI: 1.7-11.6]) ( Fig. 2A) (Fig. 2B) . In addition, when the four groups of study were compared, ERs survived less than ERs, irrespective of the quality of the donor (OD/ER: 2. (Fig. 2C) .
DISCUSSION
LT is an established therapy for end-stage lung disease. However, the shortage of suitable donors remains a limiting factor in increasing the number of LTs performed. Given the scarcity of such an extremely valuable asset, several strategies have been proposed to expand the lung donor pool. Thus, many transplant centres started to liberalize the strict donor-selection criteria to minimize the gap between demand and supply [12, 13] , using lungs from older donors [12] [13] [14] [15] , with low PaO 2 /FiO 2 [16, 17] , with mild pulmonary infiltrates on chest X-rays [12] or heavy smokers [18] .
In our study, the use of extended criteria donors did not increase the need for cardiopulmonary bypass during the procedure, the incidence of PGD or 30-day mortality. When we analysed our results transplanting donor lungs with low oxygenation ratios, we found that early outcomes were not different in terms of 30-day mortality or incidence of PGD (but in our study, donors with oxygenation ratios below 300 mmHg were not considered for transplantation in any case). Nevertheless, an oxygenation index below 300 mmHg at the time of the organ offer should not be considered a contraindication for LT, but rather an opportunity to communicate with the donor team and to aggressively manage the potential donor [19] .
Before doing this study, our clinical impression was that the use of EDs did not impair LT outcomes when the recipient fit well, but did impair the results if the patient was in poor clinical condition. However, the possible impact of using marginal donor lungs in critically ill patients (the high-risk recipient) has not been carefully assessed in the literature. The severity of recipient illness may impact on LT outcomes. Thus, pretransplant mechanical ventilation has been associated with post-transplant mortality, but a recent study of 8040 LT demonstrated that the reduction in posttransplant survival by pretransplant ventilator support is dependent on recipient diagnosis. Patients with underlying fibrotic lung showed 3-5-fold higher odds of death within the first 6 months post-transplantation [20] . In our early experience with paediatric LT [21] , we reported a 35% rate of recipients on mechanical ventilation as opposed to only 10% of adults. However, no deleterious effects of mechanical ventilation were observed in these patients when compared with non-ventilated ones.
Rather than dealing with all these criteria separately, what we really wanted to analyse were the results of LT according to donor status (optimal or marginal) and recipient status (optimal or high risk). We found that among Group 2 (OD/ER), more SLTs were performed, and CPB was needed in nearly one-third of cases, compared with Group 1 (OD/OR). Furthermore, there was a trend towards higher 30-day mortality, although not significant. Recipient PaO 2 /FiO 2 , development of PGD, 30-day and long-term survival did not compare unfavourably with the OD/OR group, suggesting that when the LT candidate fits well, the outcomes of LT are not impaired with the use of marginal grafts. The results obtained in Group 4 (ED/ER) support this observation as, despite it was the worst possible donor-to-recipient combination, recipient PaO 2 /FiO 2 at 24 h post-transplant, development of PGD and 30-day mortality were not worse than those of Group 1 (the 'ideal' combination) or those of Group 3. Furthermore, mortality in the OD/ER group was even worse. This contrasts with the experience reported by the group of Toronto [22] , which found that 30-day mortality was higher when ED lungs were transplanted into 'guideline' recipients (15.6%), and much higher when 'nonguideline' recipients received lungs from EDs (22.2%).
In our study, we observed a trend towards a delayed onset of BOS in patients receiving optimal lung grafts as compared with marginal ones. On the contrary, the onset of BOS was similar between ERs and ORs, suggesting that, as expected, the development of BOS is more dependent on the quality of the donor than on recipient characteristics, as reported previously [23] .
We have demonstrated that recipient long-term survival is not influenced by donor status (optimal/extended). Interestingly, ER status as opposed to optimal status negatively influenced long-term outcomes of LT. Thus, we observed an acute drop in ER median survival from 8.5 to 2.7 years. In this sense, we believe that recipient characteristics clearly determine the results of LT. In the last decades, the percentage of LTs performed in adults older than 60 years has increased in our Institution (data not shown). As advancing age itself implies associated comorbidities, one should expect poorer outcomes following LT. It is likely that advancing age itself might not be an absolute contraindication for LT in an otherwise 'healthy' recipient, but the presence of additional relative contraindications might preclude successful outcomes following LT. Note that a considerable number of patients in our ER group were diagnosed with IPF, a condition that has been classically associated with worse outcomes than other indications after LT. In this regard, Sundaresan et al. [13] postulated that some degree of reversible lung dysfunction can be tolerable in DLT or in SLT for emphysema. On the contrary, donor graft should be of high quality in case of primary pulmonary hypertension, or in SLT for IPF. In our opinion, marginally acceptable donor lungs can be safely used in both optimal and extended criteria recipients. Nevertheless, there is a subgroup of candidates, those with pulmonary fibrotic disease complicated with secondary pulmonary hypertension, in which SLT using marginal grafts appears to be avoidable.
Several limitations must be considered when evaluating the results reported herein. (i) Data regarding donor smoking history were missing in 17% of cases in our database (typically, in the early years of our programme) and we were not able to obtain them given the retrospective nature of our study. (ii) We designed our study by stratifying donors and recipients according to optimal or extended status, so four possible donor-to-recipient combination groups were created. But it is important to remark that each subject in an extended group may have fulfilled more than two definition criteria, so it is very difficult to determine the impact of each criterion on LT separately. Particularly, IPF patients are usually older and many of them had developed secondary pulmonary hypertension before undergoing LT, leading to an increased use of CPB. (iii) We ignored whether the use of donor lungs with oxygenation ratios of <300 would have impacted on our outcomes following LT, as to date it remains a definite criterion for accepting or rejecting a lung offer. (iv) We did not account for changes in surgical technique, preservation methods and immunosuppressive regimens over time, which could have had some influence on the data analysis. (v) Defining criteria of EDs and ERs, even though following general criteria of previous reports, were chosen arbitrarily. (vi) This study was not designed to determine independent risk factors of poor outcomes after LT that could be related to donor-recipient status combinations (thus, a multivariate analysis has not been performed), but to analyse the influence of such combinations on four major end-points: 30-day mortality, PGD, BOS and long-term survival. Although we aimed at constructing a homogeneous study group, other confounding factors might have had an influence. These circumstances might have biased the results to some degree but not, in our opinion, to such an extent as would invalidate the main conclusions drawn from the study.
In summary, EDs can be safely used to increase the lung donor pool. However, we identified a subgroup of lung transplant candidates, the high-risk recipients, who behave worse, especially those diagnosed with pulmonary fibrosis. They are expected to have worse outcomes following LT, irrespective of the quality of the lung graft. The shortage of donors for LT highlights the need for strict selection of LT candidates, to ensure that there is a maximum benefit and better use of such a scarce resource.
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APPENDIX. CONFERENCE DISCUSSION
Dr J. Dark (Newcastle Upon Tyne, UK): I have no conflicts. You very nicely showed that the extended donor is not as much of a problem as we had thought, and this adds to the increasing international acceptance of this information. I hate looking at registry data, but here is a slide from the ISHLT with data on a very large number of transplants showing that donor age really doesn't have an impact anymore. And I might comment that your donors were not extended according to many international modern terms. The average age was still less than 40; the mean oxygenation index was greater than 400. The commonest reason for deciding that they were extended donors was an abnormal chest X-ray, and you have already indicated that that's a reversible phenomenon. In fact it was demonstrated as long ago as 1995 by the St. Louis group that that could be reversed.
You have, however, demonstrated very clearly, and this is in concordance with international data, that the recipient is important. My criticism is that you have performed a univariate rather than a multivariate analysis. Many of the older patients have interstitial lung disease, have IPS, and they also have pulmonary hypertension, and you cannot disentangle from your analysis which of these is the most important phenomenon.
I would like you to address the question of whether you are identifying some patients who, although falling within acceptable criteria on individual variables, might not be candidates for surgery because they are just too high-risk, the IPF patient who is over 60 with pulmonary hypertension perhaps, and that is particularly important this year when the transplant community is reviewing the international acceptance guidelines.
I would make a minor point that your BOS data really tells us nothing at all. You don't even show a very convincing trend, I don't think. You talk about PGD, and I would be interested to know how you define this. One of my questions, though, is whether there has been a change over 20 years. This is a large cohort from a major centre; it is a 20-year experience. Did you, for instance, look at the first decade compared with the second decade?
Again, this brings us back to the univariate analysis problem. You demonstrate that older patients having IPF have worse outcomes and many of them have single-lung transplants. Can you separate out those various influences? Here is a slide showing that single lungs in general do worse.
However, to come back to the extended donor, there are some specific variables which are emerging as important. This is a slide with some data that we published last year looking at smoking in donors from a very large UK cohort. There is indisputably a disadvantage if your donor smokes. It is not as great as the disadvantage of not having a transplant, as the paper showed. Can I ask how you discussed these particular donor variables with potential recipients? Do you inform them of the problem of the smoking donor so vividly described here?
I think your presentation adds to the body of knowledge, and it is a pleasure to see lung transplantation being discussed at the ESTS.
Dr Moreno: Turning to your question about the influence of the time periods in this series, we have not analysed the impact of time on our experience. During this time, the main changes we introduced have been the preservation solution and the immunosuppression regimen. We used modified Euro-Collins before 2001 and Perfadex thereafter. Regarding immunosuppression regimens, we switched from cyclosporine to tacrolimus and from azathioprine to mycophenolate in many patients, not in all. However, it seems to me that if any changes did occur during this time, they would have been distributed homogeneously among the four groups of the study, and furthermore, two years ago we published our experience with donor assessment in three periods of time and we did not find any significant differences.
Concerning your question about the multivariate analysis, I agree with you that a multivariate analysis would have given us more information regarding the impact of each variable on lung transplant outcomes. However, the aim of our study was not to analyse the impact of age or smoking history or mechanical ventilation before lung transplantation on our results, because this has been already studied. Many transplant centres have published their results with the use of these donors.
The aim of our study was to know our results when matching the four possible combinations and to identify the candidate who best fits a lung donor. We are performing an additional analysis comparing the survival of fibrotic candidates. Of course, they are old and many of them have secondary pulmonary hypertension. We will analyse their mortality while on the waiting list compared with their survival after lung transplantation.
In relation to the question about the single-or double-lung procedures, I know this is a very controversial issue. If you look at the data of the last ISHLT report, you can see that there is a long-term survival benefit of double-lung transplantation in these recipients. However, our policy is to perform singlelung transplantation in fibrotic recipients unless they are young or have secondary pulmonary hypertension. Furthermore, given the shortage of donors, we try to perform a twinning procedure using the lungs of a single donor in two different recipients whenever possible.
Regarding the last question about smoking, in our series we defined an extended donor as one having a smoking history greater than 20 pack-years. These data were not available for every patient; we didn't know these data in 17% of patients. It seems to me that there is a difference between a 40-year-old donor with a 20 pack-year history, current smoker, and a 60-year-old ex-smoker who gave up smoking 20 years before.
I read with interest the work of the UK transplant group published last year. They compared lung transplant outcomes using smoking donors and nonsmoking ones with a cohort of patients awaiting lung transplantation, and their three-year survival was worse when using smoking donors. However, it was better than waiting for a non-smoking one.
Dr M. Hussein (Riyadh, Saudi Arabia): I have one comment. You mentioned the challenge test, the oxygen pressure over FiO2 less than 350. Normally the standard challenge test is 300 and most of the centres are working on the figure of 300, not 350.
Second, a question. Regarding your donors, did you used prolonged ventilated donors or not, because some centres are putting five days of ventilation as extended donor criteria also. This nine hours of prolonged ischaemic time, what was the highest ischaemic time? You answered the question about the type of preservation solution, but my question is are you also using antegrade and retrograde perfusion, because it is quite a long period, more than nine hours, of ischaemic time.
Dr Moreno: It is our policy to use donors with an oxygenation index not lower than 300-350 mmHg. At the beginning of our programme we were more selective with the use of the donors, so it was nearer to 350 than 300. We also used donors with prolonged mechanical ventilation before lung transplantation. This is one of the extended criteria, and is included in this cohort of patients.
Regarding the nine hours of ischaemic time, we are in a region in the south of Spain in which the distances are quite considerable, and we also have donors in the Canary Islands, which are several thousand kilometres away from our centre. So our ischaemic times are a little bit longer than other groups in Spain.
Regarding the retrograde perfusion, we performed both antegrade and retrograde, and we published it several years previously.
Dr V. Petrauskas (Panevezys, Lithuania): I would like to ask you whether any of the recipients underwent retransplantation during your trial, and if so, were these excluded from the trial? Dr Moreno: We excluded 11 retransplantations from this analysis. Dr H. Date (Kyoto, Japan): When you have an extended recipient, very sick, dying, with pulmonary hypertension, whatever, would you like to try to find a good donor or bad donor? A very simple question.
Dr Moreno: Ideally we would like to use a good one. But the problem is that in our series we have a great proportion of recipients who had cystic fibrosis. So we tried to match the ideal donors to these recipients, and obviously the rest of the donors go to fibrotic patients who usually are older. So this is the reason we have more extended donors to extended recipients in our series.
